{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.5","upperLimit":"39.6","value":"27.5"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"19.5","value":"7.1"},{"groupId":"OG002","lowerLimit":"3.1","upperLimit":"20.3","value":"9.3"},{"groupId":"OG003","lowerLimit":"0.1","upperLimit":"17.2","value":"3.3"},{"groupId":"OG004","lowerLimit":"31.6","upperLimit":"56.0","value":"43.5"},{"groupId":"OG005","lowerLimit":"16.3","upperLimit":"67.7","value":"40.0"},{"groupId":"OG006","lowerLimit":"40.6","upperLimit":"78.5","value":"60.7"},{"groupId":"OG007","lowerLimit":"0.0","upperLimit":"70.8","value":"0.0"},{"groupId":"OG008","lowerLimit":"27.3","upperLimit":"64.0","value":"45.2"},{"groupId":"OG009","lowerLimit":"37.7","upperLimit":"73.6","value":"56.3"},{"groupId":"OG010","lowerLimit":"34.1","upperLimit":"54.3","value":"44.0"},{"groupId":"OG011","lowerLimit":"44.9","upperLimit":"70.9","value":"58.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"69"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"28"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"31"},{"groupId":"OG009","value":"32"},{"groupId":"OG010","value":"100"},{"groupId":"OG011","value":"60"}],"units":"Participants"}],"description":"Percentage of patients with a best overall response defined as confirmed CR or PR per RECIST 1.1 by investigator assessment.\n\nCR: Disappearance of all non-nodal target and non-target lesions. In addition, any pathological lymph nodes assigned as target and non-target lesions must have a reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG000","title":"Cohort 1a: Pre-treated Patients With MET GCN ≥ 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 6 and \\< 10 treated with INC280 at 400 mg BID as second or third line (2/3L)","id":"OG001","title":"Cohort 1b: Pre-treated Patients With MET GCN ≥ 6 and < 10 (2/3L)"},{"description":"Pre-treated patients with MET GCN ≥ 4 and \\< 6 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG002","title":"Cohort 2: Pre-treated Patients With MET GCN ≥ 4 and < 6 (2/3L)"},{"description":"Pre-treated patients with MET GCN \\< 4 treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG003","title":"Cohort 3: Pre-treated Patients With MET GCN < 4 (2/3L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)","id":"OG004","title":"Cohort 4: Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)","id":"OG005","title":"Cohort 5a: Treatment-naïve Patients With MET GCN ≥10 (1L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)","id":"OG006","title":"Cohort 5b: Treatment-naïve Patients With MET Mutation Regardless of MET GCN (1L)"},{"description":"Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)","id":"OG007","title":"Cohort 6.1 (Expansion of Cohort 1a): Pre-treated Patients MET GCN ≥ 10 Without MET Mutation (2L)"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)","id":"OG008","title":"Cohort 6.2 (Expansion of Cohort 4): Pre-treated Patients With MET Mutation (2L)"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)","id":"OG009","title":"Cohort 7 (Expansion of Cohort 5b): Treatment-naïve With MET Mutation Regardless of MET GCN (1L)"},{"description":"All pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L). (Participants from Cohort 4 and Cohort 6.2)","id":"OG010","title":"Cohort 4 + Cohort 6.2: All Pre-treated Patients With MET Mutation Regardless of MET GCN (2/3L)"},{"description":"All treatment naive patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as first line (1L) (Participants from Cohort 5b and Cohort 7)","id":"OG011","title":"Cohort 5b + Cohort 7: All Treatment-naive With MET Mutation Regardless of MET GCN (1L)"}],"paramType":"NUMBER","populationDescription":"FAS, including all subjects who received at least one dose of capmatinib.","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years","title":"ORR by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}